Altasciences And VoxCell Partner To Advance 3D Preclinical Research In Drug Discovery

Altasciences and VoxCell BioInnovation have announced a strategic partnership aimed at transforming early-stage drug development by integrating human-relevant 3D tissue technology with comprehensive preclinical services. The alliance will combine Altasciences’ drug development expertise with VoxCell’s cutting-edge bioprinted tissue models to improve predictability in preclinical testing. 

“We’re proud to partner with VoxCell BioInnovation to bring next-generation tissue modeling into the early stages of drug development. This collaboration aligns with our commitment to the 3Rs as well as to innovative, efficient solutions that improve data quality and accelerate decisions for our clients,” said Steve Mason, Co-Chief Operating Officer at Altasciences. 

VoxCell’s proprietary high-resolution 3D bioprinted tissues are designed to replicate the complex structure of human tumors and biological systems, offering more accurate platforms for assessing drug efficacy, safety, and toxicity. By adopting this approach early in the drug development process, both companies hope to reduce time-to-clinic and boost the likelihood of success in investigational therapies.

“Our mission has always been to make drug screening more human-relevant and predictive. Altasciences shares this forward-thinking approach, and we’re excited to work together to support pharmaceutical and biotech companies in making faster, more informed decisions,” said Karolina Valente, CEO of VoxCell BioInnovation. 

The partnership will initially focus on ocular drug screening and may expand into other therapeutic areas. This collaboration reflects a joint commitment to innovation and smarter science in preclinical research, aiming to accelerate discoveries and deliver better outcomes for patients worldwide.